drugset / Trial / NCT02916537
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057
Phase 1
Completed
20 enrolled
Cancer Targeted Technology
University of California, San Francisco · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The purpose of this study is to test a novel diagnostic Positron Emission Tomography (PET) imaging agent for safety and biodistribution. The agent binds Prostate Specific Membrane Antigen (PSMA) and is designed to detect prostate tumors.
Timeline
- Start
- 2016-09
- Primary completion
- 2017-08-28
- Completion
- 2017-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTT1057 | Small molecule | 20 ug | Intravenous |
| Subject | CTT1057 | Small molecule | 370 mbq | Intravenous |